Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretrovira...
Saved in:
| Published in | The Lancet (British edition) Vol. 359; no. 9300; pp. 30 - 36 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Elsevier Ltd
05.01.2002
Lancet Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes.
In 123 patients, we did PCR analyses of the gene for the multidrug-resistance transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5. We measured concentrations in plasma of the antiretroviral agents efavirenz and nelfinavir by high-performance liquid-chromatography, and measured levels of P-glycoprotein expression, CD4-cell count, and HIV-1 viraemia.
Median drug concentrations in patients with the MDR1 3435 TT, CT, and CC genotypes were at the 30th, 50th, and 75th percentiles, respectively (p=0·0001). In patients with CYP2D6 extensive-metaboliser or poor-metaboliser alleles, median drug concentrations were at percentiles 45 and 62·5, respectively (p=0·04). Patients with the MDR1 TT genotype 6 months after starting treatment had a greater rise in CD4-cell count (257 cells/μL) than patients with the CT (165 cells/μL) and CC (121cells/μL) genotype (p=0·0048), and the best recovery of naive CD4-cells.
The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. |
|---|---|
| AbstractList | SummaryBackgroundHIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes.MethodsIn 123 patients, we did PCR analyses of the gene for the multidrug-resistance transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5. We measured concentrations in plasma of the antiretroviral agents efavirenz and nelfinavir by high-performance liquid-chromatography, and measured levels of P-glycoprotein expression, CD4-cell count, and HIV-1 viraemia.FindingsMedian drug concentrations in patients with the MDR1 3435 TT, CT, and CC genotypes were at the 30th, 50th, and 75th percentiles, respectively (p=0·0001). In patients with CYP2D6 extensive-metaboliser or poor-metaboliser alleles, median drug concentrations were at percentiles 45 and 62·5, respectively (p=0·04). Patients with the MDR1 TT genotype 6 months after starting treatment had a greater rise in CD4-cell count (257 cells/μL) than patients with the CT (165 cells/μL) and CC (121cells/μL) genotype (p=0·0048), and the best recovery of naive CD4-cells.InterpretationThe polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes. In 123 patients, we did PCR analyses of the gene for the multidrug-resistance transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5. We measured concentrations in plasma of the antiretroviral agents efavirenz and nelfinavir by high-performance liquid-chromatography, and measured levels of P-glycoprotein expression, CD4-cell count, and HIV-1 viraemia. Median drug concentrations in patients with the MDR1 3435 TT, CT, and CC genotypes were at the 30th, 50th, and 75th percentiles, respectively (p=0.0001). In patients with CYP2D6 extensive-metaboliser or poor-metaboliser alleles, median drug concentrations were at percentiles 45 and 62.5, respectively (p=0.04). Patients with the MDR1 TT genotype 6 months after starting treatment had a greater rise in CD4-cell count (257 cells/microL) than patients with the CT (165 cells/microL) and CC (121 cells/microL) genotype (p=0.0048), and the best recovery of naïve CD4-cells. The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes. In 123 patients, we did PCR analyses of the gene for the multidrug-resistance transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5. We measured concentrations in plasma of the antiretroviral agents efavirenz and nelfinavir by high-performance liquid-chromatography, and measured levels of P-glycoprotein expression, CD4-cell count, and HIV-1 viraemia. Median drug concentrations in patients with the MDR1 3435 TT, CT, and CC genotypes were at the 30th, 50th, and 75th percentiles, respectively (p=0.0001). In patients with CYP2D6 extensive-metaboliser or poor-metaboliser alleles, median drug concentrations were at percentiles 45 and 62.5, respectively (p=0.04). Patients with the MDR1 TT genotype 6 months after starting treatment had a greater rise in CD4-cell count (257 cells/microL) than patients with the CT (165 cells/microL) and CC (121 cells/microL) genotype (p=0.0048), and the best recovery of naïve CD4-cells. The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes. In 123 patients, we did PCR analyses of the gene for the multidrug-resistance transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5. We measured concentrations in plasma of the antiretroviral agents efavirenz and nelfinavir by high-performance liquid-chromatography, and measured levels of P-glycoprotein expression, CD4-cell count, and HIV-1 viraemia. Median drug concentrations in patients with the MDR1 3435 TT, CT, and CC genotypes were at the 30th, 50th, and 75th percentiles, respectively (p=0·0001). In patients with CYP2D6 extensive-metaboliser or poor-metaboliser alleles, median drug concentrations were at percentiles 45 and 62·5, respectively (p=0·04). Patients with the MDR1 TT genotype 6 months after starting treatment had a greater rise in CD4-cell count (257 cells/μL) than patients with the CT (165 cells/μL) and CC (121cells/μL) genotype (p=0·0048), and the best recovery of naive CD4-cells. The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. |
| Author | Decosterd, Laurent A Back, David J Furrer, Hansjakob Telenti, Amalio Marzolini, Catia Fellay, Jacques Chave, Jean-Philippe Retelska, Dorota Vernazza, Pietro Pantaleo, Giuseppe Ruiz, Lidia Eap, Chin B Schinkel, Alfred H Opravil, Milos Meaden, Emma R Buclin, Thierry |
| Author_xml | – sequence: 1 givenname: Jacques surname: Fellay fullname: Fellay, Jacques organization: Division of Infectious Diseases – sequence: 2 givenname: Catia surname: Marzolini fullname: Marzolini, Catia organization: Division of Clinical Pharmacology – sequence: 3 givenname: Emma R surname: Meaden fullname: Meaden, Emma R organization: Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK – sequence: 4 givenname: David J surname: Back fullname: Back, David J organization: Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK – sequence: 5 givenname: Thierry surname: Buclin fullname: Buclin, Thierry organization: Division of Clinical Pharmacology – sequence: 6 givenname: Jean-Philippe surname: Chave fullname: Chave, Jean-Philippe organization: Hospital of La Source, Lausanne – sequence: 7 givenname: Laurent A surname: Decosterd fullname: Decosterd, Laurent A organization: Division of Clinical Pharmacology – sequence: 8 givenname: Hansjakob surname: Furrer fullname: Furrer, Hansjakob organization: University Hospital of Bern, Bern – sequence: 9 givenname: Milos surname: Opravil fullname: Opravil, Milos organization: University Hospital of Zurich, Zurich – sequence: 10 givenname: Giuseppe surname: Pantaleo fullname: Pantaleo, Giuseppe organization: Division of Immunology – sequence: 11 givenname: Dorota surname: Retelska fullname: Retelska, Dorota organization: Division of Infectious Diseases – sequence: 12 givenname: Lidia surname: Ruiz fullname: Ruiz, Lidia organization: Retrovirology Laboratory, University Hospital Germans Trias i Pujol, Barcelona, Spain – sequence: 13 givenname: Alfred H surname: Schinkel fullname: Schinkel, Alfred H organization: Division of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, Netherlands – sequence: 14 givenname: Pietro surname: Vernazza fullname: Vernazza, Pietro organization: Hospital of St-Gallen, St-Gallen – sequence: 15 givenname: Chin B surname: Eap fullname: Eap, Chin B organization: University Hospital of Lausanne, Switzerland; Unit of Biochemistry and Clinical Psychopharmacology, University Hospital of Lausanne – sequence: 16 givenname: Amalio surname: Telenti fullname: Telenti, Amalio email: amalio.telenti@chuv.hospvd.ch organization: Division of Infectious Diseases |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13407832$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11809184$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV1rFDEUhoNU7Lb6E5SgCHoxejKTyYc3IqXaQkHwC-9CJnOmmzKTWZPMlv4Xf6xpd7FX4lXg8Jzzhvc5IgdhDkjIUwZvGDDx9iswDpWQjXgF9WuQtRSVekBWjEtetVz-PCCrv8ghOUrpCgC4gPYROWRMgWaKr8jvL5g2c0hI80xtyD5ijvPWRzvSHNHmCUOmPtCz8x8Vq3wY0GXsy6T3W98vdkz02uc1teOIo3d0a6MvdxKdB5rXSKdlzL6PyyWNmHzKNriSFW0osTFjpOwdtXSztnGybr7EgNm7RFNe-pvH5OFQAvDJ_j0m3z-efjs5qy4-fzo_-XBROa5VrrpWtVoxqYWQg1C27xoneNtrJXkHjZXQdg02Qg8CdMfASt3h0KlCgm0a2RyTF7u7mzj_WjBlczUvMZRIU4PQuhZCs0I9_xfFtAYBgosCtTvIxTmliIPZRD_ZeGMYmFtx5k6cubVioDZ34owqe8_2x5duwv5-a2-qAC_3gE3OjkNp0Pl0zzUcpGrqwr3fcVgK23qMJjmPpfS-qHXZ9LP_z1f-ABEbuKQ |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1097_QAI_0b013e318042e1c3 crossref_primary_10_24075_brsmu_2018_068 crossref_primary_10_2217_pme_14_7 crossref_primary_10_1038_emi_2012_15 crossref_primary_10_1517_14622416_6_2_115 crossref_primary_10_2217_pgs_09_53 crossref_primary_10_1310_MUQC_QXBC_8118_BPM5 crossref_primary_10_1007_s10928_009_9124_x crossref_primary_10_1097_00002030_200307250_00016 crossref_primary_10_2165_00003088_200443140_00003 crossref_primary_10_1124_pr_117_013706 crossref_primary_10_1016_j_placenta_2010_02_010 crossref_primary_10_1038_sj_jcbfm_9600414 crossref_primary_10_1097_00002030_200211220_00017 crossref_primary_10_1186_s13073_016_0372_2 crossref_primary_10_1586_14737159_5_5_755 crossref_primary_10_1097_FPC_0b013e3282eff934 crossref_primary_10_1248_bpb_27_261 crossref_primary_10_1586_14787210_1_1_75 crossref_primary_10_1038_sj_bjc_6605789 crossref_primary_10_1097_00008571_200210000_00004 crossref_primary_10_1007_s00580_012_1581_8 crossref_primary_10_1007_BF02696655 crossref_primary_10_2217_pgs_10_43 crossref_primary_10_1371_journal_pmed_0030085 crossref_primary_10_1111_j_0013_9580_2005_31904_x crossref_primary_10_1124_jpet_102_043547 crossref_primary_10_1002_jps_21411 crossref_primary_10_1097_QAD_0b013e328343817b crossref_primary_10_1517_17425255_2_5_651 crossref_primary_10_1016_S1470_2045_05_70538_6 crossref_primary_10_1097_FTD_0b013e31828c1581 crossref_primary_10_1038_sj_clpt_6100157 crossref_primary_10_1016_j_pharmthera_2006_04_009 crossref_primary_10_1111_j_1365_2125_2007_02903_x crossref_primary_10_1093_infdis_jis508 crossref_primary_10_2133_dmpk_23_223 crossref_primary_10_1016_j_hivar_2014_03_001 crossref_primary_10_1097_00054725_200403000_00014 crossref_primary_10_1097_JCP_0b013e31821084dc crossref_primary_10_1038_ncomms9608 crossref_primary_10_1007_s12272_020_01294_3 crossref_primary_10_1081_DMR_28805 crossref_primary_10_1128_AAC_00907_08 crossref_primary_10_1111_j_1600_0609_2004_00228_x crossref_primary_10_1007_s11095_006_0279_5 crossref_primary_10_1016_j_ajog_2007_02_019 crossref_primary_10_3389_fgene_2022_940661 crossref_primary_10_1124_pr_58_2_7 crossref_primary_10_2165_00003088_200544120_00005 crossref_primary_10_1111_j_1399_3046_2004_00223_x crossref_primary_10_1128_AAC_47_1_130_137_2003 crossref_primary_10_1157_13116752 crossref_primary_10_2217_pgs_09_12 crossref_primary_10_1007_s00228_003_0567_5 crossref_primary_10_1097_QCO_0b013e3282f42224 crossref_primary_10_1007_s11904_006_0018_x crossref_primary_10_1016_S1734_1140_11_70593_X crossref_primary_10_1016_j_canlet_2005_04_040 crossref_primary_10_1177_135965350400900610 crossref_primary_10_1002_jps_21623 crossref_primary_10_1097_QAI_0b013e3181bf648a crossref_primary_10_1007_s00280_009_1029_2 crossref_primary_10_1097_00002030_200317004_00006 crossref_primary_10_1016_j_atherosclerosis_2005_05_025 crossref_primary_10_1517_14656566_6_14_2455 crossref_primary_10_1097_00008571_200304000_00003 crossref_primary_10_1002_ibd_21608 crossref_primary_10_1073_pnas_0504163102 crossref_primary_10_1038_leu_2014_6 crossref_primary_10_1007_s00228_009_0725_5 crossref_primary_10_2165_00003088_200544090_00004 crossref_primary_10_1200_JCO_2004_10_093 crossref_primary_10_1016_S1470_2045_03_01142_2 crossref_primary_10_1517_17425255_2011_553188 crossref_primary_10_1097_01_qai_0000182627_28595_01 crossref_primary_10_1002_jin2_32 crossref_primary_10_1517_phgs_5_2_139_27486 crossref_primary_10_1159_000367962 crossref_primary_10_1086_507101 crossref_primary_10_1097_01_TP_0000137789_58694_B4 crossref_primary_10_1016_j_toxlet_2005_12_007 crossref_primary_10_1016_j_meegid_2009_09_018 crossref_primary_10_1097_QAI_0b013e3181f52f0c crossref_primary_10_1097_QAD_0b013e328336abfc crossref_primary_10_1016_j_tig_2003_09_008 crossref_primary_10_1177_0091270004268128 crossref_primary_10_2165_00129785_200303050_00001 crossref_primary_10_1002_ana_21012 crossref_primary_10_1097_00007890_200212150_00002 crossref_primary_10_1016_j_ejphar_2005_10_068 crossref_primary_10_1111_j_1472_8206_2005_00324_x crossref_primary_10_4238_vol9_2gmr813 crossref_primary_10_1081_DMR_200033458 crossref_primary_10_1016_j_ejps_2021_105986 crossref_primary_10_1016_j_bcp_2011_07_081 crossref_primary_10_1056_NEJMra020526 crossref_primary_10_1097_01_COH_0000221600_64659_d3 crossref_primary_10_2217_14622416_10_3_477 crossref_primary_10_1007_s10787_021_00921_9 crossref_primary_10_1097_00008571_200208000_00004 crossref_primary_10_1097_00008571_200404000_00005 crossref_primary_10_1002_jcph_165 crossref_primary_10_1038_sj_clpt_6100452 crossref_primary_10_3748_wjg_v12_i23_3636 crossref_primary_10_1016_j_jns_2011_11_027 crossref_primary_10_1128_AAC_00194_11 crossref_primary_10_1097_01_qai_0000225013_53568_69 crossref_primary_10_1016_j_bjid_2018_09_002 crossref_primary_10_1097_00007691_200408000_00018 crossref_primary_10_1097_00002030_200501280_00006 crossref_primary_10_1177_135965350501000307 crossref_primary_10_1086_505988 crossref_primary_10_1002_hep_21359 crossref_primary_10_3851_IMP1931 crossref_primary_10_1097_00002030_200303070_00018 crossref_primary_10_1182_blood_2004_05_1747 crossref_primary_10_2217_14622416_9_7_905 crossref_primary_10_1002_cpdd_22 crossref_primary_10_1097_00008571_200208000_00002 crossref_primary_10_1097_QAD_0b013e328011d7c1 crossref_primary_10_1186_1471_2350_11_111 crossref_primary_10_1002_jps_20967 crossref_primary_10_1080_09674845_2016_1264212 crossref_primary_10_1002_rmv_454 crossref_primary_10_1016_j_bbrc_2004_05_116 crossref_primary_10_1345_aph_1E614 crossref_primary_10_1007_s10549_013_2545_7 crossref_primary_10_1111_j_1365_2125_2007_03093_x crossref_primary_10_1080_14656566_2018_1515916 crossref_primary_10_2217_14622416_8_9_1169 crossref_primary_10_1016_S0140_6736_02_09411_4 crossref_primary_10_1038_sj_tpj_6500465 crossref_primary_10_1111_j_1365_2125_2004_02182_x crossref_primary_10_29413_ABS_2021_6_6_2_12 crossref_primary_10_1097_QAD_0b013e3282ef9695 crossref_primary_10_1002_jps_20717 crossref_primary_10_2217_14622416_8_3_227 crossref_primary_10_1097_00019052_200304000_00013 crossref_primary_10_1097_01_aids_0000183626_74299_77 crossref_primary_10_1081_DMR_200033473 crossref_primary_10_1111_j_1528_1167_2005_46304_x crossref_primary_10_1111_j_1558_5646_2007_00025_x crossref_primary_10_1590_S0104_59702005000200006 crossref_primary_10_1097_01_aids_0000161766_13782_2f crossref_primary_10_1586_17512433_1_1_5 crossref_primary_10_1007_s10928_017_9519_z crossref_primary_10_1016_S0140_6736_02_08921_3 crossref_primary_10_1517_17425255_2011_562891 crossref_primary_10_1080_15376520600558333 crossref_primary_10_1586_14737159_2_5_411 crossref_primary_10_1111_j_1365_2125_2009_03499_x crossref_primary_10_1016_S1368_7646_03_00005_0 crossref_primary_10_1093_jac_dkh487 crossref_primary_10_1111_j_1365_2125_2007_03039_x crossref_primary_10_1017_S0265021505210955 crossref_primary_10_1002_bdd_597 crossref_primary_10_1111_j_1742_7843_2008_00283_x crossref_primary_10_1016_j_bbmt_2011_08_019 crossref_primary_10_1016_S0379_4172_06_60027_9 crossref_primary_10_1016_j_critrevonc_2005_01_005 crossref_primary_10_1046_j_1365_2362_2003_01133_x crossref_primary_10_1517_17425255_3_2_197 crossref_primary_10_1177_0269881104047278 crossref_primary_10_1146_annurev_pharmtox_43_100901_140233 crossref_primary_10_1097_01_tp_0000231874_53240_ba crossref_primary_10_1186_1471_2334_13_256 crossref_primary_10_1016_j_cbpc_2023_109677 crossref_primary_10_1097_01_TP_0000114594_21317_A5 crossref_primary_10_1097_00126334_200308150_00001 crossref_primary_10_1128_AAC_48_4_1073_1081_2004 crossref_primary_10_2133_dmpk_20_391 crossref_primary_10_1086_499056 crossref_primary_10_1016_j_addr_2016_05_001 crossref_primary_10_1007_s00109_002_0416_5 crossref_primary_10_1097_01_fpc_0000172241_42546_d3 crossref_primary_10_3109_07853890_2011_572905 crossref_primary_10_1097_FPC_0b013e3282f85e36 crossref_primary_10_29413_ABS_2022_7_5_1_7 crossref_primary_10_1186_1471_2334_13_261 crossref_primary_10_1038_nrg1229 crossref_primary_10_1097_01_MIB_0000186492_43191_d5 crossref_primary_10_1093_jac_dki314 crossref_primary_10_1097_FTD_0b013e318225384f crossref_primary_10_1038_sj_tpj_6500403 crossref_primary_10_1038_sj_clpt_6100385 crossref_primary_10_1517_14656566_8_10_1441 crossref_primary_10_1128_AAC_04952_14 crossref_primary_10_1038_nrn1728 crossref_primary_10_1080_17425255_2018_1478964 crossref_primary_10_1517_17425251003601953 crossref_primary_10_2165_00003088_200645020_00007 crossref_primary_10_1007_s11033_012_1906_3 crossref_primary_10_2165_00003088_200645020_00006 crossref_primary_10_1128_CMR_00059_05 crossref_primary_10_1007_s00406_006_0664_4 crossref_primary_10_1097_00007691_200412000_00015 crossref_primary_10_1007_s40262_016_0456_6 crossref_primary_10_1093_hmg_ddh099 crossref_primary_10_1177_0091270003253617 crossref_primary_10_1046_j_1469_0691_2002_00408_x crossref_primary_10_1080_15376520600558424 crossref_primary_10_1310_0873_BVDP_AKAY_445U crossref_primary_10_1016_j_tips_2004_06_002 crossref_primary_10_1038_sj_tpj_6500413 crossref_primary_10_1093_jac_dki308 crossref_primary_10_1038_ng1437 crossref_primary_10_1016_j_bbagen_2006_08_003 crossref_primary_10_1016_j_canlet_2005_06_051 crossref_primary_10_1007_s40262_015_0267_1 crossref_primary_10_1097_QAI_0b013e3181fe4c89 crossref_primary_10_2217_17469600_2_1_69 crossref_primary_10_1007_s00109_002_0417_4 crossref_primary_10_1517_17425247_3_1_23 crossref_primary_10_1038_clpt_2010_314 crossref_primary_10_2165_00129785_200404030_00001 crossref_primary_10_1016_S0213_005X_08_76509_1 crossref_primary_10_1124_pr_111_005553 crossref_primary_10_1016_S1367_5931_02_00340_X crossref_primary_10_1080_00498250801923855 crossref_primary_10_1590_S0100_879X2005000900014 crossref_primary_10_1177_0091270005274507 crossref_primary_10_1097_FPC_0000000000000106 crossref_primary_10_1046_j_1365_2125_2003_01843_x crossref_primary_10_1080_10543400802369012 crossref_primary_10_1016_S1471_4914_02_02354_7 crossref_primary_10_1007_s11904_004_0005_z crossref_primary_10_1146_annurev_pharmtox_48_113006_094753 crossref_primary_10_1086_421557 crossref_primary_10_1200_JCO_2005_05_128 crossref_primary_10_1007_s00228_005_0926_5 crossref_primary_10_1248_yakushi_123_773 crossref_primary_10_1097_00002030_200301240_00010 crossref_primary_10_1097_01_qco_0000191507_48481_10 crossref_primary_10_1016_j_gene_2013_03_020 crossref_primary_10_1016_j_meegid_2015_11_014 crossref_primary_10_1097_01_aids_0000196122_91633_04 crossref_primary_10_1111_j_1365_2125_2009_03516_x crossref_primary_10_1097_01_aids_0000432537_92958_73 crossref_primary_10_1146_annurev_med_56_082103_104724 crossref_primary_10_1128_AAC_00672_12 crossref_primary_10_1177_0091270003257222 crossref_primary_10_1128_AAC_00283_10 crossref_primary_10_1155_2016_2587094 crossref_primary_10_1056_NEJMoa021986 crossref_primary_10_1046_j_1365_2362_33_s2_4_x crossref_primary_10_1097_QAI_0b013e31817bec05 crossref_primary_10_1097_00126334_200408150_00006 crossref_primary_10_1097_00008571_200405000_00006 crossref_primary_10_1002_ddr_10359 crossref_primary_10_1086_507097 crossref_primary_10_1111_j_1365_2125_2008_03093_x crossref_primary_10_1016_S0213_005X_08_76605_9 crossref_primary_10_1034_j_1600_6143_2003_00077_x crossref_primary_10_1080_00498250701570251 crossref_primary_10_1093_jac_dky190 crossref_primary_10_1517_17425255_2014_854330 crossref_primary_10_2165_00003088_200443090_00001 crossref_primary_10_1371_journal_pone_0055197 crossref_primary_10_1097_01_fpc_0000178311_02878_83 crossref_primary_10_2165_00003088_200342030_00002 crossref_primary_10_2217_pgs_16_7 crossref_primary_10_1038_sj_gene_6364123 crossref_primary_10_1208_s12248_013_9528_9 crossref_primary_10_1016_j_tips_2009_10_001 crossref_primary_10_1097_00002030_200209270_00010 crossref_primary_10_1089_aid_2009_0044 crossref_primary_10_1128_AAC_48_3_918_923_2004 crossref_primary_10_1080_10673220600642895 crossref_primary_10_1200_JCO_2005_04_8496 crossref_primary_10_1007_s11033_007_9206_z crossref_primary_10_1111_j_1365_2125_2006_02619_x crossref_primary_10_1371_journal_pone_0059419 crossref_primary_10_1097_01_MIB_0000186488_53493_c3 crossref_primary_10_1016_S0213_005X_08_76507_8 crossref_primary_10_2165_00129785_200303030_00006 crossref_primary_10_1016_S0198_8859_02_00426_3 crossref_primary_10_1016_S0928_0987_03_00038_1 crossref_primary_10_1093_hmg_ddi494 crossref_primary_10_1111_j_1432_2277_2008_00679_x crossref_primary_10_2217_17410541_3_3_239 crossref_primary_10_1080_00365540500469535 crossref_primary_10_1053_j_gastro_2004_11_019 crossref_primary_10_1046_j_1529_8817_2003_00124_x crossref_primary_10_1111_1468_0440_00226 crossref_primary_10_1093_jac_dkp351 crossref_primary_10_1111_j_1440_1746_2007_04848_x crossref_primary_10_2133_dmpk_19_1 crossref_primary_10_1097_00007691_200404000_00005 crossref_primary_10_1002_jps_23005 crossref_primary_10_1097_FTD_0b013e3181f0634c crossref_primary_10_1373_49_4_672 crossref_primary_10_2217_pgs_14_1 crossref_primary_10_1208_s12248_021_00592_y crossref_primary_10_1089_aid_2010_0172 crossref_primary_10_1097_00008571_200311000_00003 crossref_primary_10_1038_sj_tpj_6500374 crossref_primary_10_1097_00008571_200311000_00002 crossref_primary_10_1097_00008571_200311000_00001 crossref_primary_10_1177_026988110401800408 crossref_primary_10_1007_s11033_007_9142_y crossref_primary_10_1017_S0265021505000839 crossref_primary_10_2217_pgs_15_16 crossref_primary_10_1016_S0140_6736_02_07899_6 crossref_primary_10_1111_j_1742_7843_2006_pto_246_x crossref_primary_10_1182_blood_2003_06_2105 crossref_primary_10_1097_00007691_200404000_00017 crossref_primary_10_1592_phco_23_8_979_32881 crossref_primary_10_1016_j_lfs_2010_09_012 crossref_primary_10_1017_S0265021505220951 crossref_primary_10_3892_ol_2015_3138 crossref_primary_10_1086_421774 crossref_primary_10_1097_FPC_0b013e3282f7046f crossref_primary_10_1089_apc_2008_0176 crossref_primary_10_1097_INF_0b013e318168d5d0 crossref_primary_10_1097_00126334_200311010_00006 crossref_primary_10_2217_14622416_7_4_587 crossref_primary_10_1038_clpt_2010_172 crossref_primary_10_1016_S1730_1270_10_60010_0 crossref_primary_10_1016_j_drugpo_2014_06_013 crossref_primary_10_1007_s10620_010_1251_0 crossref_primary_10_1016_S0966_842X_03_00177_X crossref_primary_10_1046_j_1365_2958_2003_03597_x crossref_primary_10_1016_S1730_1270_10_60045_8 crossref_primary_10_1097_00008571_200406000_00007 crossref_primary_10_1038_jhg_2009_20 crossref_primary_10_1128_AAC_01537_08 crossref_primary_10_1097_00008571_200308000_00006 crossref_primary_10_1016_S0966_842X_02_02427_7 crossref_primary_10_2165_00129785_200505010_00005 crossref_primary_10_2217_pgs_13_176 crossref_primary_10_1097_FPC_0b013e328165249f crossref_primary_10_2165_11317350_000000000_00000 crossref_primary_10_1002_bmc_521 crossref_primary_10_1007_s00228_017_2235_1 crossref_primary_10_1016_S0213_005X_05_75161_2 crossref_primary_10_24075_vrgmu_2018_068 crossref_primary_10_1111_j_1742_7843_2010_00627_x crossref_primary_10_1093_jac_dkp317 crossref_primary_10_1007_s00228_004_0855_8 crossref_primary_10_1016_S0169_409X_02_00064_9 crossref_primary_10_2217_pme_15_54 crossref_primary_10_1016_j_ygyno_2007_10_029 crossref_primary_10_1097_QAD_0b013e32830163ad crossref_primary_10_2165_00002018_200427150_00002 crossref_primary_10_4161_bbug_3_1_19011 crossref_primary_10_1016_j_placenta_2005_08_001 crossref_primary_10_1097_00002030_200406180_00009 crossref_primary_10_1111_j_1528_1167_2008_01661_x crossref_primary_10_1097_01_fpc_0000197467_21964_67 crossref_primary_10_1097_QAD_0b013e32830e011f crossref_primary_10_1097_01_fpc_0000230413_97596_fa crossref_primary_10_2165_00003495_200363080_00002 crossref_primary_10_1310_hct1406_313 crossref_primary_10_1007_s12272_011_1104_1 crossref_primary_10_1016_S0888_7543_03_00117_4 crossref_primary_10_1080_17425255_2022_2112175 crossref_primary_10_1124_jpet_104_065383 crossref_primary_10_1089_aid_2006_22_153 crossref_primary_10_1097_FPC_0b013e328351f3c1 crossref_primary_10_1097_00126334_200310010_00001 crossref_primary_10_1258_ijsa_2008_008369 crossref_primary_10_1128_JVI_78_21_12022_12029_2004 crossref_primary_10_1002_cpt_43 crossref_primary_10_2217_pgs_2023_0058 crossref_primary_10_1517_17425255_2014_930128 crossref_primary_10_1111_j_1365_2125_2005_02392_x crossref_primary_10_1101_gr_1965304 crossref_primary_10_1093_infdis_jir262 crossref_primary_10_1186_1471_2164_7_111 crossref_primary_10_1186_1755_8794_1_21 crossref_primary_10_1111_tri_12018 crossref_primary_10_1097_QAI_0b013e318183a425 crossref_primary_10_1097_00041552_200311000_00006 crossref_primary_10_1016_j_antiviral_2009_09_001 crossref_primary_10_1515_CCLM_2003_063 crossref_primary_10_1038_clpt_2009_78 crossref_primary_10_1007_s11904_004_0013_z crossref_primary_10_1097_00126334_200408010_00008 crossref_primary_10_1080_00498250600944300 crossref_primary_10_1007_s00108_005_1489_3 crossref_primary_10_1111_j_1365_2125_2009_03438_x crossref_primary_10_1016_j_amjcard_2004_01_014 crossref_primary_10_1080_00498250701867889 crossref_primary_10_1016_S0213_005X_04_73106_7 crossref_primary_10_1016_j_gene_2014_12_051 crossref_primary_10_2133_dmpk_21_506 crossref_primary_10_1177_1756285608097775 crossref_primary_10_1097_00002030_200401230_00002 crossref_primary_10_1097_01_ftd_0000245770_75097_3f crossref_primary_10_1097_FTD_0b013e31824868f3 crossref_primary_10_1002_ddr_10390 crossref_primary_10_1177_0897190007304823 crossref_primary_10_1097_QAD_0000000000002308 crossref_primary_10_2217_pgs_10_94 crossref_primary_10_2217_pgs_09_142 crossref_primary_10_1177_0897190007304819 crossref_primary_10_1007_s00430_005_0010_x crossref_primary_10_1097_QAI_0b013e31816fdc5f crossref_primary_10_2217_17469600_1_2_203 crossref_primary_10_1007_s00228_004_0879_0 crossref_primary_10_1128_CMR_00168_19 crossref_primary_10_1097_QAD_0b013e32832c412b crossref_primary_10_1081_DMR_120018247 crossref_primary_10_2217_pgs_13_111 crossref_primary_10_1517_14656566_6_15_2593 crossref_primary_10_1086_344179 crossref_primary_10_22625_2072_6732_2021_13_1_21_28 crossref_primary_10_2217_pgs_11_55 crossref_primary_10_1038_sj_bjp_0705940 crossref_primary_10_3390_ijms19113594 crossref_primary_10_1053_gast_2003_50010 crossref_primary_10_1080_10245330310001638974 crossref_primary_10_1097_TP_0b013e3181c342fd crossref_primary_10_1097_01_ftd_0000185771_82620_ee crossref_primary_10_1517_17425255_1_3_473 crossref_primary_10_1016_j_dmpk_2016_06_001 crossref_primary_10_1093_jac_dkw005 crossref_primary_10_2217_pgs_11_84 crossref_primary_10_1016_S0213_005X_05_75160_0 crossref_primary_10_1007_s11033_007_9109_z crossref_primary_10_1248_bpb_27_939 crossref_primary_10_3390_app13116576 crossref_primary_10_1248_bpb_25_1391 crossref_primary_10_1080_00498250903060077 crossref_primary_10_1017_S0265021505240942 |
| Cites_doi | 10.1172/JCI1269 10.1038/71577 10.1073/pnas.93.9.4001 10.1002/ajh.2830490411 10.1038/sj.bjp.0701845 10.1038/86882 10.1016/0092-8674(91)90141-K 10.1097/00008571-199608000-00008 10.1097/00002030-200104130-00009 10.1016/S0378-4347(99)00573-3 10.1097/00007691-199806000-00013 10.1067/mcp.2001.117412 10.1016/0140-6736(90)92086-W 10.1067/mcp.2000.104391 10.1016/S0140-6736(01)05579-9 10.1124/mol.56.2.383 10.1016/S0021-9258(17)40694-6 10.1097/00002030-200104130-00002 10.1096/fasebj.14.3.516 10.1172/JCI118214 10.1073/pnas.97.7.3473 10.2165/00003495-200059030-00014 10.1097/00002030-200002180-00005 10.1097/00008571-200106000-00003 10.1023/A:1026553626537 10.1097/00008571-200104000-00005 10.1002/eji.1830250549 10.1016/S0169-409X(99)00021-6 10.1128/AAC.42.12.3157 10.1016/S0140-6736(00)03232-3 |
| ContentType | Journal Article |
| Copyright | 2002 Elsevier Ltd 2002 INIST-CNRS Copyright Lancet Ltd. Jan 5, 2002 Copyright Elsevier Limited Jan 5, 2002 |
| Copyright_xml | – notice: 2002 Elsevier Ltd – notice: 2002 INIST-CNRS – notice: Copyright Lancet Ltd. Jan 5, 2002 – notice: Copyright Elsevier Limited Jan 5, 2002 |
| CorporateAuthor | for the Swiss HIV Cohort Study Swiss HIV Cohort Study |
| CorporateAuthor_xml | – name: for the Swiss HIV Cohort Study – name: Swiss HIV Cohort Study |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TT 0TZ 0U~ 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI PSYQQ Q9U S0X |
| DOI | 10.1016/S0140-6736(02)07276-8 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef News PRO Pharma and Biotech Premium PRO Global News & ABI/Inform Professional ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database (ProQuest) Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database (ProQuest) Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary AUTh Library subscriptions: ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences ProQuest Consumer Health Database Health & Medical Collection (Alumni Edition) ProQuest Health Management Database PML(ProQuest Medical Library) ProQuest Psychology Database ProQuest research library ProQuest Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic SIRS Editorial |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student News PRO ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection Environmental Sciences and Pollution Management Global News & ABI/Inform Professional Health Research Premium Collection Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts Pharma and Biotech Premium PRO SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) |
| DatabaseTitleList | ProQuest One Psychology MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 36 |
| ExternalDocumentID | 98625891 10_1016_S0140_6736_02_07276_8 11809184 13407832 S0140673602072768 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US |
| GroupedDBID | --- --K --M .55 .CO .GJ 04C 0R~ 123 1B1 1RT 1~5 29L 3EH 3O- 3V. 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88A 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAXUO AAYOK ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABLVK ABMAC ABOCM ABUWG ABYKQ ACGFS ACGOD ACIUM ACPRK ACRLP ADBBV ADMUD AEKER AENEX AFKRA AFKWA AFRAH AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AHPSJ AITUG AJBFU AJOXV AJRQY AKVCP ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AN0 ANZVX AQUVI ARTTT AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS ESX EVS EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GNUQQ GUQSH HCIFZ HMCUK HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0L M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 MVM N9A NAPCQ O-L O9- OZT P-9 P2P PC. PQQKQ PRG PROAC PSQYO PSYQQ R2- RIG ROL RPZ S0X SAD SDF SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TH9 TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU XFK XPP Y6R YYM ZA5 ZMT ZXP .1- .FO 08R 1P~ 41~ 8WZ A6W AAEJM AAKAS AAQXK AAUGY ABMZM ABTAH ACRZS ADZCM AEVXI AFFNX AFRHN AJJEV AJUYK AKALU ASPBG AVWKF AZFZN D0S EPT FEDTE FGOYB GBLVA IQODW NHB OD. OO~ OVD P-8 Q~Q TEORI UHU WOQ WUQ YYQ Z5R ZGI ZY4 ~G0 AAMRU AAXKI AFCTW AKRWK ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION HVGLF 0TT 0TZ 0U~ 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PQEST PQUKI Q9U |
| ID | FETCH-LOGICAL-c498t-b58598179667f68adb3c645d9874b03a705b3e369f609b10a79befb88ad0a3373 |
| IEDL.DBID | BENPR |
| ISSN | 0140-6736 |
| IngestDate | Thu Oct 10 21:00:46 EDT 2024 Thu Oct 10 21:01:53 EDT 2024 Thu Sep 26 16:34:06 EDT 2024 Sat Sep 28 07:41:19 EDT 2024 Sun Oct 22 16:04:51 EDT 2023 Fri Feb 23 02:27:28 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9300 |
| Keywords | Human Pharmacogenetics Treatment resistance Multiple HIV-1 virus P Glycoprotein Retroviridae Lentivirus Blood plasma Result Infection Virus Allele Chemotherapy Treatment Gene Viral disease Genetics Antiviral Human immunodeficiency virus Quantitative analysis Polymorphism |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c498t-b58598179667f68adb3c645d9874b03a705b3e369f609b10a79befb88ad0a3373 |
| PMID | 11809184 |
| PQID | 199060646 |
| PQPubID | 40246 |
| PageCount | 7 |
| ParticipantIDs | proquest_journals_2069926691 proquest_journals_199060646 crossref_primary_10_1016_S0140_6736_02_07276_8 pubmed_primary_11809184 pascalfrancis_primary_13407832 elsevier_sciencedirect_doi_10_1016_S0140_6736_02_07276_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2002-01-05 |
| PublicationDateYYYYMMDD | 2002-01-05 |
| PublicationDate_xml | – month: 01 year: 2002 text: 2002-01-05 day: 05 |
| PublicationDecade | 2000 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2002 |
| Publisher | Elsevier Ltd Lancet Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Lancet – name: Elsevier Limited |
| References | Kuehl, Zhang, Lin (bib16) 2001; 27 Ameyaw, Regateiro, Li (bib34) 2001; 11 Lavie, Liscovitch (bib33) 2000; 17 Smit, Schinkel, Weert, Meijer (bib29) 1998; 124 Schuetz, Umbenhauer, Yasuda (bib31) 2000; 57 Jones, Hoggard, Sales (bib4) 2001; 15 Schinkel, Wagenaar, van Deemter, Mol, Borst (bib10) 1995; 96 Ramratnam, Mittler, Zhang (bib23) 2000; 6 de Morais, Wilkinson, Blaisdell (bib6) 1994; 269 Marzolini, Telenti, Buclin (bib9) 2000; 740 Carrillo, Ramos, Agundez, Martinez, Benitez (bib11) 1998; 20 Li, Chan (bib5) 1999; 39 Yamashita, Phair, Munoz (bib18) 2001; 15 Huang, Wring, Woolley (bib32) 2001; 29 Hoffmeyer, Burk, von Richter (bib12) 2000; 97 Kim, Fromm, Wandel (bib3) 1998; 101 Lee, Ramachandra, Jeang (bib21) 2000; 14 Huisman, Smit, Schinkel (bib19) 2000; 14 Johansson, Lundqvist, Dahl, Ingelman-Sundberg (bib8) 1996; 6 Choo, Leake, Wandel (bib27) 2000; 28 Kim, Leake, Choo (bib25) 2001; 70 Greub, Ledergerber, Battegay (bib17) 2000; 356 Hitzl, Drescher, van der (bib26) 2001; 11 MacDonald, Bommhardt, Cerottini (bib2) 1995; 25 Pilarski, Paine, McElhaney, Cass, Belch (bib20) 1995; 49 Schaeffeler, Eichelbaum, Brinkmann (bib22) 2001; 358 Schuetz, Schinkel, Relling, Schuetz (bib30) 1996; 93 Heim, Meyer (bib7) 1990; 336 Srinivas, Middlemas, Flynn, Fridland (bib13) 1998; 42 Chaudhary, Roninson (bib1) 1991; 66 Bardsley-Elliot, Plosker (bib14) 2000; 59 Sata, Sapone, Elizondo (bib15) 2000; 67 Tanabe, Ieiri, Nagata (bib24) 2001; 297 Gutmann, Fricker, Drewe, Toeroek, Miller (bib28) 1999; 56 12086787 - Lancet. 2002 Jun 15;359(9323):2114; author reply 2214-5 Kuehl (10.1016/S0140-6736(02)07276-8_bib16) 2001; 27 Huisman (10.1016/S0140-6736(02)07276-8_bib19) 2000; 14 Lavie (10.1016/S0140-6736(02)07276-8_bib33) 2000; 17 Schuetz (10.1016/S0140-6736(02)07276-8_bib31) 2000; 57 Srinivas (10.1016/S0140-6736(02)07276-8_bib13) 1998; 42 MacDonald (10.1016/S0140-6736(02)07276-8_bib2) 1995; 25 Greub (10.1016/S0140-6736(02)07276-8_bib17) 2000; 356 Li (10.1016/S0140-6736(02)07276-8_bib5) 1999; 39 Marzolini (10.1016/S0140-6736(02)07276-8_bib9) 2000; 740 Hitzl (10.1016/S0140-6736(02)07276-8_bib26) 2001; 11 Jones (10.1016/S0140-6736(02)07276-8_bib4) 2001; 15 Huang (10.1016/S0140-6736(02)07276-8_bib32) 2001; 29 Smit (10.1016/S0140-6736(02)07276-8_bib29) 1998; 124 Sata (10.1016/S0140-6736(02)07276-8_bib15) 2000; 67 Kim (10.1016/S0140-6736(02)07276-8_bib25) 2001; 70 Kim (10.1016/S0140-6736(02)07276-8_bib3) 1998; 101 Gutmann (10.1016/S0140-6736(02)07276-8_bib28) 1999; 56 Johansson (10.1016/S0140-6736(02)07276-8_bib8) 1996; 6 Lee (10.1016/S0140-6736(02)07276-8_bib21) 2000; 14 Schaeffeler (10.1016/S0140-6736(02)07276-8_bib22) 2001; 358 Hoffmeyer (10.1016/S0140-6736(02)07276-8_bib12) 2000; 97 Ameyaw (10.1016/S0140-6736(02)07276-8_bib34) 2001; 11 Schinkel (10.1016/S0140-6736(02)07276-8_bib10) 1995; 96 Heim (10.1016/S0140-6736(02)07276-8_bib7) 1990; 336 Pilarski (10.1016/S0140-6736(02)07276-8_bib20) 1995; 49 Ramratnam (10.1016/S0140-6736(02)07276-8_bib23) 2000; 6 Choo (10.1016/S0140-6736(02)07276-8_bib27) 2000; 28 Schuetz (10.1016/S0140-6736(02)07276-8_bib30) 1996; 93 Tanabe (10.1016/S0140-6736(02)07276-8_bib24) 2001; 297 Chaudhary (10.1016/S0140-6736(02)07276-8_bib1) 1991; 66 de Morais (10.1016/S0140-6736(02)07276-8_bib6) 1994; 269 Carrillo (10.1016/S0140-6736(02)07276-8_bib11) 1998; 20 Bardsley-Elliot (10.1016/S0140-6736(02)07276-8_bib14) 2000; 59 Yamashita (10.1016/S0140-6736(02)07276-8_bib18) 2001; 15 |
| References_xml | – volume: 66 start-page: 85 year: 1991 end-page: 94 ident: bib1 article-title: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells publication-title: Cell contributor: fullname: Roninson – volume: 49 start-page: 323 year: 1995 end-page: 335 ident: bib20 article-title: Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging publication-title: Am J Hematol contributor: fullname: Belch – volume: 269 start-page: 15419 year: 1994 end-page: 15422 ident: bib6 article-title: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans publication-title: J Biol Chem contributor: fullname: Blaisdell – volume: 11 start-page: 217 year: 2001 end-page: 221 ident: bib34 article-title: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity publication-title: Pharmacogenetics contributor: fullname: Li – volume: 59 start-page: 581 year: 2000 end-page: 620 ident: bib14 article-title: Nelfinavir: an update on its use in HIV infection publication-title: Drugs contributor: fullname: Plosker – volume: 67 start-page: 48 year: 2000 end-page: 56 ident: bib15 article-title: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity publication-title: Clin Pharmacol Ther contributor: fullname: Elizondo – volume: 96 start-page: 1698 year: 1995 end-page: 1705 ident: bib10 article-title: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A publication-title: J Clin Invest contributor: fullname: Borst – volume: 28 start-page: 655 year: 2000 end-page: 660 ident: bib27 article-title: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes publication-title: Drug Metab Dispos contributor: fullname: Wandel – volume: 97 start-page: 3473 year: 2000 end-page: 3478 ident: bib12 article-title: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo publication-title: Proc Natl Acad Sci USA contributor: fullname: von Richter – volume: 6 start-page: 351 year: 1996 end-page: 355 ident: bib8 article-title: PCR-based genotyping for duplicated and deleted CYP2D6 genes publication-title: Pharmacogenetics contributor: fullname: Ingelman-Sundberg – volume: 20 start-page: 319 year: 1998 end-page: 324 ident: bib11 article-title: Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A publication-title: Ther Drug Monit contributor: fullname: Benitez – volume: 27 start-page: 383 year: 2001 end-page: 391 ident: bib16 article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression publication-title: Nat Genet contributor: fullname: Lin – volume: 356 start-page: 1800 year: 2000 end-page: 1805 ident: bib17 article-title: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study publication-title: Lancet contributor: fullname: Battegay – volume: 56 start-page: 383 year: 1999 end-page: 389 ident: bib28 article-title: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins publication-title: Mol Pharmacol contributor: fullname: Miller – volume: 336 start-page: 529 year: 1990 end-page: 532 ident: bib7 article-title: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification publication-title: Lancet contributor: fullname: Meyer – volume: 39 start-page: 81 year: 1999 end-page: 103 ident: bib5 article-title: Transport, metabolism and elimination mechanisms of anti-HIV agents publication-title: Adv Drug Deliv Rev contributor: fullname: Chan – volume: 14 start-page: 516 year: 2000 end-page: 522 ident: bib21 article-title: Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter publication-title: FASEB J contributor: fullname: Jeang – volume: 101 start-page: 289 year: 1998 end-page: 294 ident: bib3 article-title: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors publication-title: J Clin Invest contributor: fullname: Wandel – volume: 358 start-page: 383 year: 2001 end-page: 384 ident: bib22 article-title: Frequency of C3435T polymorphism of publication-title: Lancet contributor: fullname: Brinkmann – volume: 70 start-page: 189 year: 2001 end-page: 199 ident: bib25 article-title: Identification of functionally variant MDR1 alleles among European Americans and African Americans publication-title: Clin Pharmacol Ther contributor: fullname: Choo – volume: 14 start-page: 237 year: 2000 end-page: 242 ident: bib19 article-title: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors publication-title: AIDS contributor: fullname: Schinkel – volume: 11 start-page: 293 year: 2001 end-page: 298 ident: bib26 article-title: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells publication-title: Pharmacogenetics contributor: fullname: van der – volume: 740 start-page: 43 year: 2000 end-page: 58 ident: bib9 article-title: Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction publication-title: J Chromatogr B Biomed Appl contributor: fullname: Buclin – volume: 297 start-page: 1137 year: 2001 end-page: 1143 ident: bib24 article-title: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene publication-title: J Pharmacol Exp Ther contributor: fullname: Nagata – volume: 17 start-page: 253 year: 2000 end-page: 259 ident: bib33 article-title: Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences publication-title: Glycoconj J contributor: fullname: Liscovitch – volume: 15 start-page: 675 year: 2001 end-page: 681 ident: bib4 article-title: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport publication-title: AIDS contributor: fullname: Sales – volume: 42 start-page: 3157 year: 1998 end-page: 3162 ident: bib13 article-title: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters publication-title: Antimicrob Agents Chemother contributor: fullname: Fridland – volume: 57 start-page: 188 year: 2000 end-page: 197 ident: bib31 article-title: Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes publication-title: Mol Pharmacol contributor: fullname: Yasuda – volume: 25 start-page: 1457 year: 1995 end-page: 1460 ident: bib2 article-title: Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes publication-title: Eur J Immunol contributor: fullname: Cerottini – volume: 15 start-page: 735 year: 2001 end-page: 746 ident: bib18 article-title: Immunologic and virologic response to highly active antiretroviral therapy in the multicenter AIDS cohort study publication-title: AIDS contributor: fullname: Munoz – volume: 6 start-page: 82 year: 2000 end-page: 85 ident: bib23 article-title: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy publication-title: Nat Med contributor: fullname: Zhang – volume: 29 start-page: 754 year: 2001 end-page: 760 ident: bib32 article-title: Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors publication-title: Drug Metab Dispos contributor: fullname: Woolley – volume: 124 start-page: 416 year: 1998 end-page: 424 ident: bib29 article-title: Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted publication-title: Br J Pharmacol contributor: fullname: Meijer – volume: 93 start-page: 4001 year: 1996 end-page: 4005 ident: bib30 article-title: P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans publication-title: Proc Natl Acad Sci USA contributor: fullname: Schuetz – volume: 101 start-page: 289 year: 1998 ident: 10.1016/S0140-6736(02)07276-8_bib3 article-title: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors publication-title: J Clin Invest doi: 10.1172/JCI1269 contributor: fullname: Kim – volume: 6 start-page: 82 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib23 article-title: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy publication-title: Nat Med doi: 10.1038/71577 contributor: fullname: Ramratnam – volume: 93 start-page: 4001 year: 1996 ident: 10.1016/S0140-6736(02)07276-8_bib30 article-title: P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.9.4001 contributor: fullname: Schuetz – volume: 29 start-page: 754 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib32 article-title: Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors publication-title: Drug Metab Dispos contributor: fullname: Huang – volume: 49 start-page: 323 year: 1995 ident: 10.1016/S0140-6736(02)07276-8_bib20 article-title: Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging publication-title: Am J Hematol doi: 10.1002/ajh.2830490411 contributor: fullname: Pilarski – volume: 124 start-page: 416 year: 1998 ident: 10.1016/S0140-6736(02)07276-8_bib29 article-title: Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0701845 contributor: fullname: Smit – volume: 27 start-page: 383 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib16 article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression publication-title: Nat Genet doi: 10.1038/86882 contributor: fullname: Kuehl – volume: 28 start-page: 655 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib27 article-title: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes publication-title: Drug Metab Dispos contributor: fullname: Choo – volume: 66 start-page: 85 year: 1991 ident: 10.1016/S0140-6736(02)07276-8_bib1 article-title: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells publication-title: Cell doi: 10.1016/0092-8674(91)90141-K contributor: fullname: Chaudhary – volume: 6 start-page: 351 year: 1996 ident: 10.1016/S0140-6736(02)07276-8_bib8 article-title: PCR-based genotyping for duplicated and deleted CYP2D6 genes publication-title: Pharmacogenetics doi: 10.1097/00008571-199608000-00008 contributor: fullname: Johansson – volume: 15 start-page: 735 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib18 article-title: Immunologic and virologic response to highly active antiretroviral therapy in the multicenter AIDS cohort study publication-title: AIDS doi: 10.1097/00002030-200104130-00009 contributor: fullname: Yamashita – volume: 740 start-page: 43 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib9 article-title: Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction publication-title: J Chromatogr B Biomed Appl doi: 10.1016/S0378-4347(99)00573-3 contributor: fullname: Marzolini – volume: 20 start-page: 319 year: 1998 ident: 10.1016/S0140-6736(02)07276-8_bib11 article-title: Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A publication-title: Ther Drug Monit doi: 10.1097/00007691-199806000-00013 contributor: fullname: Carrillo – volume: 57 start-page: 188 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib31 article-title: Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes publication-title: Mol Pharmacol contributor: fullname: Schuetz – volume: 70 start-page: 189 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib25 article-title: Identification of functionally variant MDR1 alleles among European Americans and African Americans publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2001.117412 contributor: fullname: Kim – volume: 336 start-page: 529 year: 1990 ident: 10.1016/S0140-6736(02)07276-8_bib7 article-title: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification publication-title: Lancet doi: 10.1016/0140-6736(90)92086-W contributor: fullname: Heim – volume: 67 start-page: 48 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib15 article-title: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2000.104391 contributor: fullname: Sata – volume: 358 start-page: 383 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib22 article-title: Frequency of C3435T polymorphism of MDR1 gene in African people publication-title: Lancet doi: 10.1016/S0140-6736(01)05579-9 contributor: fullname: Schaeffeler – volume: 56 start-page: 383 year: 1999 ident: 10.1016/S0140-6736(02)07276-8_bib28 article-title: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins publication-title: Mol Pharmacol doi: 10.1124/mol.56.2.383 contributor: fullname: Gutmann – volume: 297 start-page: 1137 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib24 article-title: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene publication-title: J Pharmacol Exp Ther contributor: fullname: Tanabe – volume: 269 start-page: 15419 year: 1994 ident: 10.1016/S0140-6736(02)07276-8_bib6 article-title: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)40694-6 contributor: fullname: de Morais – volume: 15 start-page: 675 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib4 article-title: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport publication-title: AIDS doi: 10.1097/00002030-200104130-00002 contributor: fullname: Jones – volume: 14 start-page: 516 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib21 article-title: Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter publication-title: FASEB J doi: 10.1096/fasebj.14.3.516 contributor: fullname: Lee – volume: 96 start-page: 1698 year: 1995 ident: 10.1016/S0140-6736(02)07276-8_bib10 article-title: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A publication-title: J Clin Invest doi: 10.1172/JCI118214 contributor: fullname: Schinkel – volume: 97 start-page: 3473 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib12 article-title: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.97.7.3473 contributor: fullname: Hoffmeyer – volume: 59 start-page: 581 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib14 article-title: Nelfinavir: an update on its use in HIV infection publication-title: Drugs doi: 10.2165/00003495-200059030-00014 contributor: fullname: Bardsley-Elliot – volume: 14 start-page: 237 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib19 article-title: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors publication-title: AIDS doi: 10.1097/00002030-200002180-00005 contributor: fullname: Huisman – volume: 11 start-page: 293 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib26 article-title: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells publication-title: Pharmacogenetics doi: 10.1097/00008571-200106000-00003 contributor: fullname: Hitzl – volume: 17 start-page: 253 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib33 article-title: Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences publication-title: Glycoconj J doi: 10.1023/A:1026553626537 contributor: fullname: Lavie – volume: 11 start-page: 217 year: 2001 ident: 10.1016/S0140-6736(02)07276-8_bib34 article-title: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity publication-title: Pharmacogenetics doi: 10.1097/00008571-200104000-00005 contributor: fullname: Ameyaw – volume: 25 start-page: 1457 year: 1995 ident: 10.1016/S0140-6736(02)07276-8_bib2 article-title: Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes publication-title: Eur J Immunol doi: 10.1002/eji.1830250549 contributor: fullname: MacDonald – volume: 39 start-page: 81 year: 1999 ident: 10.1016/S0140-6736(02)07276-8_bib5 article-title: Transport, metabolism and elimination mechanisms of anti-HIV agents publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(99)00021-6 contributor: fullname: Li – volume: 42 start-page: 3157 year: 1998 ident: 10.1016/S0140-6736(02)07276-8_bib13 article-title: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.12.3157 contributor: fullname: Srinivas – volume: 356 start-page: 1800 year: 2000 ident: 10.1016/S0140-6736(02)07276-8_bib17 article-title: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study publication-title: Lancet doi: 10.1016/S0140-6736(00)03232-3 contributor: fullname: Greub |
| SSID | ssj0004605 |
| Score | 2.3507085 |
| Snippet | HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune... SummaryBackgroundHIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate... |
| SourceID | proquest crossref pubmed pascalfrancis elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 30 |
| SubjectTerms | Alleles Anti-HIV Agents - blood Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral agents Antiretroviral drugs Antiviral agents ATP-Binding Cassette, Sub-Family B, Member 1 - drug effects ATP-Binding Cassette, Sub-Family B, Member 1 - physiology Benzoxazines Biocompatibility Biological and medical sciences CCR5 protein CD4 antigen Chromatography, High Pressure Liquid CYP2D6 protein Cytochrome P-450 Enzyme System - drug effects Cytochrome P-450 Enzyme System - genetics Cytochrome P450 Drug resistance Drug therapy Efavirenz Electrical impedance Female Gene amplification Gene polymorphism Genes Genes, MDR - drug effects Genes, MDR - genetics Genotype Genotypes Glycoproteins HIV HIV Infections - drug therapy HIV Protease Inhibitors - blood HIV Protease Inhibitors - therapeutic use HIV-1 Human immunodeficiency virus Humans Immunology Immunosuppressive agents Isoenzymes Logistic Models Male MDR1 protein Medical research Medical sciences Multidrug resistance Multidrug resistant organisms Mutation Nelfinavir Nelfinavir - blood Nelfinavir - therapeutic use Oxazines - blood Oxazines - therapeutic use P-Glycoprotein Patients Pharmacogenetics Pharmacology Pharmacology. Drug treatments Polymerase Chain Reaction Polymorphism Prospective Studies Proteins Recovery Treatment Outcome Viremia |
| Title | Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study |
| URI | https://dx.doi.org/10.1016/S0140-6736(02)07276-8 https://www.ncbi.nlm.nih.gov/pubmed/11809184 https://www.proquest.com/docview/199060646 https://www.proquest.com/docview/2069926691 |
| Volume | 359 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7RrYSQEOJNaFn5wAEOBmf9iN1LRatWCxIVKhTtLYpjp1oJ7S6blF_Dj2XsOLtCbeGSQ2I7kmfs-Wb8eQbgtTS-NlpK2jSioCL3mlpWc1pbhRaDc8HqSJA9U9ML8WkmZyng1iZa5bAnxo3aLesQI0cnXRmD1sTkh6ufNFSNCqerqYTGDuxOQuamEewenZx9Ob_pZmQkuW_v8Lz_unn5hk3eMrTjiurbrNP9VdXinDV9sYvb0Wi0SqcP4UGCk-RDL_9HcMcvHsPdz-nA_An8Pu85sJ50S4KTiBtcF4IIa-y04ZiT-YJMP35HN6-nZnlH5pt7Wi0JoVoSSq78mNfkF_rWgTpDlg1B7EgiIdGtry4J-u0Bi6IS4chDxvQ1yQ9IRVYpQTZqa7g02ZKY1fYpXJyefDue0lSQgdbC6I5a9C2MxiWsVNEoXTnLayWkM7oQlvGqYNJyz5VpFDM2Z1VhrG-sxpas4rzgz2C0WC78CyBcKGyvPPdGCme8RtycO2WcQwjCpcjg3SCIctXn3ShvIKSxSRklV-oM9CCuMoGHHhSUaBv-13X8l3i3P-TxlHOSwd4g7zIt8bbM0Y6j9ydUBvvXv27VNYPnvYZshw0509CzfvnvjntwL5aeCfEeuQ-jbn3lXyEC6uwYdopZgU99nI-Tyv8BX2ID6g |
| link.rule.ids | 315,786,790,12077,12244,21409,27946,27947,31743,33290,33768,43334,43603,43829,74091,74360,74648 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSICEEG9CS5kDBzgYnPUjNheEENUW2h6gRXuz4thBK6HdZZPya_ixjB1nV4gWrontSJmx55vxNzOEPJcmNEZLSdtWVFSUQVPHGk4bp9BicC5YkwiyJ2p6Jj7O5CwH3LpMqxzPxHRQ-2UTY-TopCtj0JqY8u3qB41do-Ltam6hcZVcExwXRn2uZtVFeZGJ4r7N4Hn9ZfPwBZu8ZGjFFdWX2aZbq7rDP9YOrS4ux6LJJh3cIbczmIR3g_TvkithcY9cP87X5ffJr88DAzZAvwT8hXi89TGEsMZJG4Y5zBcwPfyKTt5AzAoe5pssrQ5ioBZiw5Xv8wZ-omcdiTOwbAGRIyQ6ol-ffwP02iMSRRXClcd66Wso30ANq1weG3U1pkx2kGraPiBnBx9O309pbsdAG2F0Tx16FkbjBlaqapWuveONEtIbXQnHeF0x6XjgyrSKGVeyujIutE7jSFZzXvGHZGexXITHBLhQOF4FHowU3gSNqLn0yniPAIRLUZBXoyDsaqi6YS-go7GJTZKzuiB6FJfN0GGABBYtw_-m7v8h3u0HebrjnBRkd5S3zRu8syVacfT9hCrI3t9vt8pakEeDhmyXjRXT0K9-8u-Jz8iN6enxkT06PPm0S26mJjQx8iP3yE6_Pg9PEQv1bj8p_G8bCQO7 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSBVShcqzoaX4wAEOps76zaVCwGrLo0JA0d6sOHbQStXudpPya_ixjB1nV4gWrontSJmx55vxNzMIPRMm1EYLQZqGK8LLoImjNSO1k2AxGOO0TgTZUzk54--nYpr5T22mVQ5nYjqo_aKOMXJw0qUxYE1MedRkWsTnt-Pj5QWJHaTiTWtup3ET3VLgtMRNqqbqqhzJRHffZPMcfV0_fE5HLyhYdEn0dXZqZ1m18Peavu3F9bg02afxLrqTgSV-3WvCXXQjzO-h7U_56vw--vWlZ8MG3C0w_E446roYTljBpDXbHM_meHLyHRy-nqQVPJ6tM7ZaHIO2ODZfOZ_V-Cd42ZFEgxcNBhSJEzXRry5_YPDgIyoFdYKVh9rpK1y-whVe5lLZoLcxfbLFqb7tA3Q2fvftzYTk1gyk5kZ3xIGXYTRsZilVI3XlHaslF95oxR1llaLCscCkaSQ1rqSVMi40TsNIWjGm2EO0NV_Mwx7CjEsYLwMLRnBvggYEXXppvAcwwgQv0MtBEHbZV-CwV1DT6MgmyVldID2Iy2YY0cMDC1bif1MP_xDv5oMs3XeOCrQ_yNvmzd7aEiw6-IFcFujg77cbxS3Qo15DNsvG6mngYz_-98SnaBt03X48Of2wj26nfjQxCCQO0Fa3ugxPABZ17jDp-293yAfw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Response+to+antiretroviral+treatment+in+HIV-1-infected+individuals+with+allelic+variants+of+the+multidrug+resistance+transporter+1%3A+a+pharmacogenetics+study&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Fellay%2C+Jacques&rft.au=Marzolini%2C+Catia&rft.au=Meaden%2C+Emma+R&rft.au=Back%2C+David+J&rft.date=2002-01-05&rft.issn=0140-6736&rft.volume=359&rft.issue=9300&rft.spage=30&rft.epage=36&rft_id=info:doi/10.1016%2FS0140-6736%2802%2907276-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S0140_6736_02_07276_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |